EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

Biologic agents (also termed biologicals or biologics) are therapeutics that are synthesized by living organisms and directed against a specific determinant, for example, a cytokine or receptor. In inflammatory and autoimmune diseases, biologicals have revolutionized the treatment of several immune‐mediated disorders. Biologicals have also been tested in allergic disorders. These include agents targeting IgE; T helper 2 (Th2)‐type and Th2‐promoting cytokines, including interleukin‐4 (IL‐4), IL‐5, IL‐9, IL‐13, IL‐31, and thymic stromal lymphopoietin (TSLP); pro‐inflammatory cytokines, such as IL‐1β, IL‐12, IL‐17A, IL‐17F, IL‐23, and tumor necrosis factor (TNF); chemokine receptor CCR4; and lymphocyte surface and adhesion molecules, including CD2, CD11a, CD20, CD25, CD52, and OX40 ligand. In this task force paper of the Interest Group on Biologicals of the European Academy of Allergy and Clinical Immunology, we review biologicals that are currently available or tested for the use in various allergic and urticarial pathologies, by providing an overview on their state of development, area of use, adverse events, and future research directions.

[1]  M. Adachi,et al.  Anti-IgE therapy for allergic bronchopulmonary aspergillosis. , 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[2]  H. Simon,et al.  Novel targeted therapies for eosinophil-associated diseases and allergy. , 2015, Annual review of pharmacology and toxicology.

[3]  F. Spertini,et al.  Adverse reactions to biologic agents and their medical management , 2014, Nature Reviews Rheumatology.

[4]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[5]  R. Maciuca,et al.  Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production , 2014, Science Translational Medicine.

[6]  L. Boulet,et al.  Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. , 2014, The New England journal of medicine.

[7]  E. Zintzaras,et al.  Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: A synthesis of published evidence , 2014, Pediatric pulmonology.

[8]  S. Wenzel,et al.  Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. , 2014, The Journal of allergy and clinical immunology.

[9]  J. Bernabéu-Wittel,et al.  Successful management of Churg–Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: First documented pediatric case , 2014, Pediatric pulmonology.

[10]  A. Burks,et al.  Length Of Avoidance Period Following Peanut Oral Immunotherapy Influences Effector Cell Suppression and Clinical Outcomes , 2014 .

[11]  S. Mosesova,et al.  OX40L blockade and allergen-induced airway responses in subjects with mild asthma , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  M. Maurer,et al.  Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. , 2014, Journal of dermatological science.

[13]  R. Moss.  Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis , 2013, European Respiratory Journal.

[14]  E. Kerwin,et al.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. , 2013, American journal of respiratory and critical care medicine.

[15]  Désirée van der Heijde,et al.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[16]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[17]  M. Maurer,et al.  Neues von der internationalen Leitlinie für Diagnostik und Therapie der chronischen Urtikaria , 2013 .

[18]  T. Zuberbier,et al.  Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[19]  R. Leigh,et al.  A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma , 2013, Respiratory Research.

[20]  Ruksha Bhadresha.  Dupilumab in persistent asthma with elevated eosinophil levels , 2013, Thorax.

[21]  Simon Francis Thomsen,et al.  TNF-Alpha Inhibitors for Chronic Urticaria: Experience in 20 Patients , 2013, Journal of allergy.

[22]  S. Mosesova,et al.  Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. , 2013, The Journal of allergy and clinical immunology.

[23]  T. Zuberbier,et al.  Efficacy and safety of canakinumab in urticarial vasculitis: an open-label study. , 2013, The Journal of allergy and clinical immunology.

[24]  K. Bergmann,et al.  Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy , 2013, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[25]  F. Messeguer,et al.  Severe Refractory Atopic Dermatitis in an Adolescent Patient Successfully Treated with Ustekinumab , 2013, Annals of dermatology.

[26]  James J. Lee,et al.  The consequences of not having eosinophils , 2013, Allergy.

[27]  K. McKeage.  Omalizumab: A Review of its Use in Patients with Severe Persistent Allergic Asthma , 2013, Drugs.

[28]  P. Kuna,et al.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. , 2013, The Journal of allergy and clinical immunology.

[29]  H. Kantarjian,et al.  Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody. , 2013, Clinical lymphoma, myeloma & leukemia.

[30]  D. Broide,et al.  Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. , 2013, The Journal of allergy and clinical immunology.

[31]  M. Loza,et al.  Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. , 2013, British journal of clinical pharmacology.

[32]  L. Schnitzler,et al.  Schnitzler's syndrome: diagnosis, treatment, and follow‐up , 2013, Allergy.

[33]  T. Casale,et al.  Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. , 2013, The Journal of allergy and clinical immunology.

[34]  B. Strober,et al.  Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up , 2013, The British journal of dermatology.

[35]  Shu-Juan Jiang,et al.  Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials , 2013, PloS one.

[36]  H. Nelson.  Faculty Opinions recommendation of Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013 .

[37]  D. Leung,et al.  New era of biologic therapeutics in atopic dermatitis , 2013, Expert opinion on biological therapy.

[38]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[39]  R. Wong,et al.  Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. , 2013, Paediatric respiratory reviews.

[40]  J. Sheikh,et al.  Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. , 2013, The Journal of allergy and clinical immunology.

[41]  S. Stern,et al.  Long-term efficacy of fixed-dose omalizumab for patients with severe chronic spontaneous urticaria. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[42]  E. Kerwin,et al.  A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Moderate to Severe Asthma , 2013 .

[43]  S. Antoniu,et al.  Tralokinumab for uncontrolled asthma , 2013, Expert opinion on biological therapy.

[44]  D. Umetsu,et al.  Oral Immunotherapy for Food Allergy: Towards a New Horizon , 2012, Allergy, asthma & immunology research.

[45]  J. Schalkwijk,et al.  Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome , 2012, Annals of the rheumatic diseases.

[46]  J. Ortonne,et al.  Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study , 2012, The British journal of dermatology.

[47]  C. Bachert,et al.  Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. , 2012, The Journal of allergy and clinical immunology.

[48]  E. D. De Boever,et al.  A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. , 2013, British journal of clinical pharmacology.

[49]  S. Sánchez-Ramón,et al.  Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. , 2013, Journal of investigational allergology & clinical immunology.

[50]  A. Vatrella,et al.  The potential of biologics for the treatment of asthma , 2012, Nature Reviews Drug Discovery.

[51]  G. Hudes,et al.  Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab , 2012, Journal of asthma and allergy.

[52]  M. Gattorno,et al.  Biologic drugs in autoinflammatory syndromes. , 2012, Autoimmunity reviews.

[53]  H. Ortega,et al.  Novel targeted therapies for eosinophilic disorders. , 2012, The Journal of allergy and clinical immunology.

[54]  M. ElMallah,et al.  Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab). , 2012, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[55]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[56]  Deborah A Meyers,et al.  IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. , 2012, The Journal of allergy and clinical immunology.

[57]  T. Zuberbier,et al.  Efficacy and safety of the interleukin‐1 antagonist rilonacept in Schnitzler syndrome: an open‐label study , 2012, Allergy.

[58]  J. Reichert,et al.  Marketing approval of mogamulizumab , 2012, mAbs.

[59]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[60]  P. Calzavara-Pinton,et al.  Successful treatment of systemic cold contact urticaria with etanercept in a patient with psoriasis , 2012, The British journal of dermatology.

[61]  S. Holgate.  Innate and adaptive immune responses in asthma , 2012, Nature Medicine.

[62]  B. Strober,et al.  Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. , 2012, Journal of the American Academy of Dermatology.

[63]  R. Kolbeck,et al.  Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[64]  C. Akdis.  Therapies for allergic inflammation: refining strategies to induce tolerance , 2012, Nature Medicine.

[65]  J. Ortonne,et al.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. , 2012, The New England journal of medicine.

[66]  K. Nadeau,et al.  Changes in antigen-specific T cell number and function during oral desensitization in cow’s milk allergy enabled with omalizumab , 2012, Mucosal Immunology.

[67]  James B. Young,et al.  Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. , 2012, The Journal of allergy and clinical immunology.

[68]  M. Hoshino,et al.  Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma , 2012, Respiration.

[69]  J. Moreno,et al.  Treatment of severe refractory adult atopic dermatitis with ustekinumab , 2012, International journal of dermatology.

[70]  Aasia I. Ghazi,et al.  Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma , 2012, Expert opinion on biological therapy.

[71]  S. Chakravarty,et al.  Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. , 2011, The Journal of allergy and clinical immunology.

[72]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[73]  H. Ortega,et al.  An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. , 2011, Gastroenterology.

[74]  C. Bachert,et al.  Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. , 2011, The Journal of allergy and clinical immunology.

[75]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[76]  F. Moosig,et al.  Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. , 2011, Annals of internal medicine.

[77]  W. Calhoun,et al.  Can anti‐IgE therapy prevent airway remodeling in allergic asthma? , 2011, Allergy.

[78]  I. Tillie‐Leblond,et al.  Allergic bronchopulmonary aspergillosis and omalizumab , 2011, Allergy.

[79]  K. Leiferman,et al.  Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors. , 2011, Journal of the American Academy of Dermatology.

[80]  R. Marthan,et al.  Airway remodeling in asthma: new mechanisms and potential for pharmacological intervention. , 2011, Pharmacology & therapeutics.

[81]  K. Nadeau,et al.  Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. , 2011, The Journal of allergy and clinical immunology.

[82]  L. Gibiansky,et al.  Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor , 2011, Pharmaceutical Research.

[83]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[84]  L. Boulet,et al.  Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. , 2011, American journal of respiratory and critical care medicine.

[85]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[86]  Ó. Asensio,et al.  Effects of omalizumab in Aspergillus-associated airway disease , 2011, Thorax.

[87]  H. Sampson,et al.  Future therapies for food allergies. , 2011, The Journal of allergy and clinical immunology.

[88]  W. White,et al.  Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma , 2011, BMC pulmonary medicine.

[89]  M. Magerl,et al.  Omalizumab – an effective and safe treatment of therapy‐resistant chronic spontaneous urticaria , 2011, Allergy.

[90]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[91]  M. Kopp.  Omalizumab: Anti-IgE Therapy in Allergy , 2011, Current allergy and asthma reports.

[92]  A. Burks,et al.  A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. , 2011, The Journal of allergy and clinical immunology.

[93]  T. Casale,et al.  Future forms of immunotherapy. , 2011, The Journal of allergy and clinical immunology.

[94]  G. Stingl,et al.  Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – a randomized, placebo‐controlled and double blind pilot study , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[95]  I. Pavord,et al.  Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial , 2010, European Respiratory Journal.

[96]  M. Raffeld,et al.  Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. , 2010, The Journal of allergy and clinical immunology.

[97]  M. Cazzola,et al.  Italian real-life experience of omalizumab. , 2010, Respiratory medicine.

[98]  S. Sullivan,et al.  The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective , 2010, Allergy.

[99]  T. Zuberbier,et al.  Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria , 2010, International Archives of Allergy and Immunology.

[100]  J. Monroe,et al.  B‐cell targeted therapies in human autoimmune diseases: an updated perspective , 2010, Immunological reviews.

[101]  E. Israel,et al.  Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. , 2010, The Journal of allergy and clinical immunology.

[102]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.

[103]  Sally E Wenzel,et al.  A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. , 2010, American journal of respiratory and critical care medicine.

[104]  W. Paul,et al.  How are TH2-type immune responses initiated and amplified? , 2010, Nature Reviews Immunology.

[105]  W. Busse,et al.  A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. , 2010, The Journal of allergy and clinical immunology.

[106]  D. Furst.  The risk of infections with biologic therapies for rheumatoid arthritis. , 2010, Seminars in arthritis and rheumatism.

[107]  U. Wahn,et al.  Safety of anti‐IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[108]  W. Busse,et al.  Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. , 2010, The Journal of allergy and clinical immunology.

[109]  T. Agner,et al.  Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[110]  S. Willsie.  Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .

[111]  F. Mellot,et al.  Sustained response to mepolizumab in refractory Churg-Strauss syndrome. , 2010, The Journal of allergy and clinical immunology.

[112]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[113]  S. Holgate,et al.  Effects of omalizumab on markers of inflammation in patients with allergic asthma , 2009, Allergy.

[114]  H. Hoffman.  Therapy of autoinflammatory syndromes. , 2009, The Journal of allergy and clinical immunology.

[115]  L. Cox.  Allergy, Asthma & Clinical Immunology Open Access How Safe Are the Biologicals in Treating Asthma and Rhinitis? , 2022 .

[116]  C. Beglinger,et al.  Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial , 2009, Gut.

[117]  C. Filis,et al.  Prolonged high‐dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis , 2009, Allergy.

[118]  S. Gaffen.  Structure and signalling in the IL-17 receptor family , 2009, Nature Reviews Immunology.

[119]  E. Kerwin,et al.  A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. , 2009, American journal of respiratory and critical care medicine.

[120]  W. White,et al.  Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. , 2009, Clinical therapeutics.

[121]  K. Okubo,et al.  Re-Treatment with Omalizumab at One Year Interval for Japanese Cedar Pollen-Induced Seasonal Allergic Rhinitis Is Effective and Well Tolerated , 2009, International Archives of Allergy and Immunology.

[122]  P. Arkwright.  Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. , 2009, The Journal of allergy and clinical immunology.

[123]  K. Bergmann,et al.  Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal allergic asthma , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[124]  H. Kantarjian,et al.  Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia , 2009, Clinical Cancer Research.

[125]  M. Dougados,et al.  Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials , 2008, Annals of the rheumatic diseases.

[126]  P. Demoly,et al.  Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. , 2009, Journal of investigational allergology & clinical immunology.

[127]  W. Busse,et al.  Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. , 2008, American journal of respiratory and critical care medicine.

[128]  R. Zeldin,et al.  Treatment of chronic autoimmune urticaria with omalizumab. , 2008, The Journal of allergy and clinical immunology.

[129]  H. Simon,et al.  Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. , 2008, The Journal of allergy and clinical immunology.

[130]  C. Grohé,et al.  Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg–Strauss syndrome , 2008, Thorax.

[131]  P. Giavina-Bianchi,et al.  Omalizumab and Churg-Strauss syndrome. , 2008, The Journal of allergy and clinical immunology.

[132]  A. Šedivá,et al.  Anti-CD20 (rituximab) treatment for atopic eczema. , 2008, The Journal of allergy and clinical immunology.

[133]  N. Korman,et al.  Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. , 2008, Journal of the American Academy of Dermatology.

[134]  C. Milla,et al.  Steroid‐sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis , 2008, Pediatric pulmonology.

[135]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[136]  K. Kontou-Fili.  ALLERGY Net: High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis , 2008, Allergy.

[137]  T. Zuberbier,et al.  Successful treatment of solar urticaria with anti‐immunoglobulin E therapy , 2008, Allergy.

[138]  S. Holgate,et al.  The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial , 2008, Thorax.

[139]  P. Giavina-Bianchi,et al.  One Year Administration of Anti-IgE to a Patient with Churg-Strauss Syndrome , 2008, International Archives of Allergy and Immunology.

[140]  T. Zuberbier,et al.  Successful treatment of cholinergic urticaria with anti‐immunoglobulin E therapy , 2008, Allergy.

[141]  P. Rottoli,et al.  Churg-Strauss Vasculitis in a Patient Treated with Omalizumab , 2008, The Journal of asthma : official journal of the Association for the Care of Asthma.

[142]  P. GonzálezDelgado,et al.  Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. , 2008 .

[143]  H. Simon,et al.  Anti-CD20 (rituximab) treatment improves atopic eczema. , 2008, The Journal of allergy and clinical immunology.

[144]  V. Soriano Gómis,et al.  Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy. , 2008, Journal of investigational allergology & clinical immunology.

[145]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[146]  M. Eldon,et al.  A Randomized, Placebo-Controlled, Dose-Escalation, Phase 1 Study of the Safety and Pharmacokinetics of Amphotericin B Inhalation Powder in Healthy Subjects. , 2007 .

[147]  J. Ring,et al.  Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. , 2007, The Journal of allergy and clinical immunology.

[148]  S. Wenzel,et al.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.

[149]  Vicki Seyfert-Margolis,et al.  Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. , 2007, The Journal of allergy and clinical immunology.

[150]  M. Rose,et al.  Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab , 2007, Allergy.

[151]  R. Penn,et al.  The Role of Anti-IgE Immunoglobulin Therapy in Nasal Polyposis: A Pilot Study , 2007, American journal of rhinology.

[152]  R. Mallipeddi,et al.  Lack of response of severe steroid‐dependent chronic urticaria to rituximab , 2007, Clinical and experimental dermatology.

[153]  M. Maurer,et al.  Successful treatment of delayed pressure urticaria with anti-TNF-alpha. , 2007, The Journal of allergy and clinical immunology.

[154]  Erin G Harper,et al.  Efalizumab for severe atopic dermatitis: a pilot study in adults. , 2007, Journal of the American Academy of Dermatology.

[155]  Á. Cruz,et al.  Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[156]  M. Collins,et al.  Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. , 2006, The Journal of allergy and clinical immunology.

[157]  C. Bachert,et al.  Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. , 2006, The Journal of allergy and clinical immunology.

[158]  P. Barnes,et al.  The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-α in Asthma , 2006 .

[159]  J. Ring,et al.  No Effect of Anti-Interleukin-5 Therapy (Mepolizumab) on the Atopy Patch Test in Atopic Dermatitis Patients , 2006, International Archives of Allergy and Immunology.

[160]  J. Boyce.  Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. , 2006, The Journal of allergy and clinical immunology.

[161]  I. Pavord,et al.  Evidence of a role of tumor necrosis factor alpha in refractory asthma. , 2006, The New England journal of medicine.

[162]  C. Beadling,et al.  Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27 , 2006, Archivum Immunologiae et Therapiae Experimentalis.

[163]  G. Burmester,et al.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[164]  B. Thiers.  Tumour Necrosis Factor (TNFα) as a Novel Therapeutic Target in Symptomatic Corticosteroid Dependent Asthma , 2006 .

[165]  Vicki Seyfert-Margolis,et al.  Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. , 2006, The Journal of allergy and clinical immunology.

[166]  P. Barnes,et al.  The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. , 2006, American journal of respiratory and critical care medicine.

[167]  K. Okubo,et al.  Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. , 2006, Allergology international : official journal of the Japanese Society of Allergology.

[168]  P. Howarth,et al.  Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. , 2005, Thorax.

[169]  S. Friedlander,et al.  Etanercept is minimally effective in 2 children with atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[170]  J. Ring,et al.  Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis , 2005, Allergy.

[171]  G. Schuler,et al.  Infliximab in the treatment of moderate to severe atopic dermatitis. , 2005, Journal of the American Academy of Dermatology.

[172]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[173]  A. Togias,et al.  Omalizumab-induced reductions in mast cell FcεRI expression and function , 2004 .

[174]  T. Haverty,et al.  Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. , 2004, Blood.

[175]  A. Togias,et al.  Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. , 2004, The Journal of allergy and clinical immunology.

[176]  J. Ring,et al.  Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. , 2003, The New England journal of medicine.

[177]  K. Bergmann,et al.  Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. , 2002, The Journal of allergy and clinical immunology.

[178]  T. Casale,et al.  Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.

[179]  W. Busse,et al.  Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. , 2001, The Journal of allergy and clinical immunology.

[180]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[181]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[182]  C. Galera.  Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis , 2022 .